Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 1501 • ACR Convergence 2021
Molecular Modelling Predicts Inhibition of Functional Effects of Anti-thrombin III on Factor Xa Mediated Complement Activation by Anti- Factor Xa IgG in SLE and APS
Thomas McDonnell¹, Raj Amarnani², Valentina Spiteri², Carina Spicer³, Charis Pericleous⁴, Bahar Artim-Esen⁵, Ian Mackie¹, Marina Botto⁴, Anisur Rahman¹ and Ian Giles¹, ¹University College London, London, United Kingdom, ²University College London, London, ³Merck, Philadelphia, PA, ⁴Imperial College London, London, United Kingdom, ⁵Istanbul University School of Medicine, İstanbul, Turkey
Background/Purpose: The significance of antibodies directed against activated Factor (FXa) and thrombin (Thr) found in ~40% of patients with Systemic Lupus Erythematosus (SLE) and/or Antiphospholipid…
Abstract Number: 0075 • ACR Convergence 2021
Endothelial Cell-activating Antibodies in COVID-19
Hui Shi¹, Yu Zuo², Sherwin Navaz², Alyssa Harbaugh², Claire Hoy², Alex Gandhi², Gautam Sule², Srilakshmi Yalavarthi², Kelsey Gockman², Jacqueline Madison², Jintao Wang², Melanie zuo², Yue Shi³, Michael Maile², Yogendra Kanthi² and Jason Knight², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Shanghai Sports School, Shanghai, China (People's Republic)
Background/Purpose: Patients with COVID-19 are at high risk for occlusion of vascular beds of all sizes. Considering endothelial cell activation has regularly been described as…
Abstract Number: 0076 • ACR Convergence 2021
Predicting the Transitions Between Lupus Anticoagulant Status and Thrombosis in SLE Using a Multi-state Markov Model
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Antiphospholipid syndrome (APS) is a significant cause of morbidity and mortality in patients with SLE and lupus anticoagulant (LAC) positivity is the best predictor…
Abstract Number: 0077 • ACR Convergence 2021
Association of Lupus Nephritis and Other Clinical Features with Antiphospholipid Antibody Positivity Among Patients with Systemic Lupus Erythematosus
Prarthana Jain, Jim Oates, Dulaney Wilson and Diane Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Antiphospholipid antibody (aPL) positivity is associated with elevated risk of thrombosis among patients with SLE, but other clinical associations are less well-known. The goal…
Abstract Number: 0078 • ACR Convergence 2021
Frequency and Clinical Characteristics of Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus: The Georgia Lupus Registry
Jinan al-naqeeb¹, Gaobin Bao², Cristina Drenkard² and S Sam Lim³, ¹Emory University, Decatur, GA, ²Emory University, Atlanta, GA, ³Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Although APS was originally described in those with SLE, the epidemiology and clinical characteristics of secondary APS (2APS) has not been well described in…
Abstract Number: 0079 • ACR Convergence 2021
Association Between Preconception Complement Levels and Use of Hydroxychloroquine with Pregnancy Outcome in Patients with Primary Antiphospholipid Syndrome and Carriers of Antiphospholipid Antibodies: An International Multicenter Study
Daniele Lini¹, Cecilia Nalli², Laura Andreoli³, Francesca Crisafulli¹, Micaela Fredi¹, Maria Grazia Lazzaroni¹, Viktoria Bitsadze⁴, Antonia Calligaro⁵, Valentina Canti⁶, Roberto Caporali⁷, Francesco Carubbi⁸, Cecilia Chighizola⁹, Paola Conigliaro¹⁰, Fabrizio Conti¹¹, Caterina De Carolis¹², Teresa Del Ross⁵, Maria Favaro⁵, Maria Gerosa⁹, Annamaria Iuliano¹³, Jamilya Khizroeva⁴, Alexander Makatsariya⁴, Pier Luigi Meroni¹⁴, Marta Mosca¹⁵, Melissa Padovan¹⁶, Roberto Perricone¹⁰, Patrizia Rovere Querini⁶, Gian Domenico Sebastiani¹³, Chiara Tani¹⁷, Marta Tonello¹⁸, Simona Truglia¹¹, Dina Zucchi¹⁵, Franco Franceschini¹ and Angela Tincani¹⁹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ³University of Brescia, Brescia, Italy, ⁴Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia, ⁵Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy, ⁶Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁷Policlinico S. Matteo University, Pavia, Italy, ⁸Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, L'Aquila, Italy, ⁹University of Milan, Milan, Italy, ¹⁰Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy, ¹¹Lupus Clinic, Reumatologia, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Rome, Italy, ¹²Polymedical Center for Prevention of Recurrent Spontaneous Abortion, Rome, Italy, ¹³Rheumatology Unit, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, ¹⁴Division of Rheumatology, ASST.G Pini, Department of Clinical Sciences and Community Health, University of Milan and Istituto Auxologico Italiano, Milan, Italy, ¹⁵Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹⁶Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy, ¹⁷Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹⁸BSC, Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy, ¹⁹ASST Spedali Civili-University of Brescia, Gussago, Italy
Background/Purpose: APS is a rare autoimmune disease characterized by thrombotic events and/or pregnancy morbidities in the presence of confirmed positivity for aPL. Complement was demonstrated…
Abstract Number: 0080 • ACR Convergence 2021
One Point Increase in the Initial Damage as Measured by the Damage Index for Antiphospholipid Syndrome Predicts Mortality in a Multi-Ethnic Group of Thrombotic Antiphospholipid Syndrome Patients
Pedro Gaspar¹, Filipa Farinha², Zara Sayar³, Maria Efthymiou,⁴, Hannah Cohen³ and David Isenberg², ¹Department of Internal Medicine 2, University Hospital of Santa Maria, Lisbon, Portugal, ²Centre for Rheumatology, University College London, London, United Kingdom, ³Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁴Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom
Background/Purpose: The chronic and recurrent nature of antiphospholipid syndrome (APS) leads to damage accrual that impairs long-term functional status and survival. The Damage Index for…
Abstract Number: 0081 • ACR Convergence 2021
Thrombin Generation Assay and Lupus Anticoagulant Identify Different Populations of Patients with Antiphospholipid Antibodies
Massimo Radin¹, Alice Barinotti¹, Irene Cecchi², Silvia Grazietta Foddai¹, Elena Rubini¹, Dario Roccatello¹, Elisa Menegatti¹ and Savino Sciascia¹, ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy
Background/Purpose: Risk stratification in patients with antiphospholipid antibodies (aPL) remains a clinical challenge. We aim to evaluate the role of Thrombin Generation Assay (TGA) in…
Abstract Number: 0524 • ACR Convergence 2020
Determination of Homogenous Subgroups of Antiphospholipid Syndrome: A Cluster Analysis Based on 509 Cases
Yann Nguyen¹, Cécile Yelnik², Nathalie Morel³, Romain Paule⁴, Pierre-Yves Hatron², Romain Stammler⁵, Léo Plaçais³, Jean-Charles Piette⁶, Luc Mouthon⁷, Eric Hachulla⁸, Marc Lambert², Le Guern Véronique³ and Nathalie Costedoat-Chalumeau⁹, ¹1Department of Internal Medicine, Hôpital Beaujon, APHP Nord, Université de Paris, Clichy, Clichy, France, ²Department of Internal Medicine and Clinical Immunology, National Referral Centre for rare Systemic Auto-immune Diseases North and North-West of France (CeRAINO), CHU Lille, Hôpital Claude Huriez, Lille, France, Lille, France, ³National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France, Paris, France, ⁴Department of Internal Medicine, Hôpital Foch, Suresnes, France, Suresnes, France, ⁵National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France, Paris, ⁶Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, ⁷National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, ⁸Department of Internal Medicine and Clinical Immunology, Université de Lille, Lille, France, Lille, France, ⁹APHP, Université de Paris, Paris, France
Background/Purpose: Antiphospholipid syndrome (APS) is a heterogeneous disease, with different phenotypes which may widely vary from classical thrombotic or obstetrical manifestations to catastrophic antiphospholipid syndrome…
Abstract Number: 1680 • ACR Convergence 2020
Lupus Anticoagulant as a Predictor of Adverse Outcomes in Children with Venous Thromboembolism
Elizabeth Sloan¹ and Ayesha Zia¹, ¹UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The presence of antiphospholipid antibodies, including lupus anticoagulant (LA), is a risk factor for development of venous thromboembolism (VTE) in children. The impact of…
Abstract Number: 0525 • ACR Convergence 2020
Epidemiology of Thromboembolic Complications Among Hospitalized Patients with Antiphospholipid Syndrome in the United States
Lauren Mathias¹, Aditya Mantha², Kristen Mathias³ and Glenn Ehresmann¹, ¹University of Southern California, Division of Rheumatology, Los Angeles, CA, ²University of Southern California, Department of Medicine, Los Angeles, CA, ³University of Chicago, Department of Medicine, Chicago, IL
Background/Purpose: Antiphospholipid syndrome (APLS) is characterized by arterial and venous thrombosis, often in the setting of an underlying systemic disease. Few studies have described the…
Abstract Number: 1775 • ACR Convergence 2020
Risk Factors for Adverse Pregnancy Outcomes of Women with Positive for Antiphospholipid Antibodies Treated with Conventional Therapies
Hiromi Shimada¹, Risa Wakiya², Mai Mahmound Fahmy Mansour¹, Shusaku Nakashima¹, Mikiya Kato¹, Koichi Sugihara¹, Yusuke Ushio¹, Tomohiro Kameda¹ and Hiroaki Dobashi³, ¹Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kita-gun, Kagawa, Japan, ²Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kagawa, Kagawa, Japan, ³Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: Antiphospholipid antibodies induce several obstetric complications including recurrent spontaneous abortion, preterm birth, intrauterine fetal death. EULAR recommendations for antiphospholipid syndrome (APS) indicates low dose…
Abstract Number: 0526 • ACR Convergence 2020
Patient-Reported Outcomes in Antiphospholipid Syndrome
Julia Weiner¹, Kelsey Gockman¹, Jacqueline Madison¹, Yu Zuo², Emily Briceño¹, Vivek Nagaraja³ and Jason Knight², ¹University of Michigan, Ann Arbor, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI
Background/Purpose: PROMIS® (Patient-Reported Outcome Measurement Information System) is a set of person-centered measures that evaluates and monitors the physical, emotional, and social aspects of health.…
Abstract Number: 1792 • ACR Convergence 2020
Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE
Yevgeniya Gartshteyn¹, Roberta Vezza Alexander², John Conklin³, Thierry Dervieux⁴ and Anca Askanase⁵, ¹Columbia University College of Physicians and Surgeons, Glen Rock, NJ, ²Exagen Inc, Vista, CA, ³Exagen Inc., Vista, CA, ⁴Prometheus Biosciences Inc, San Diego, CA, ⁵Columbia University College of Physicians and Surgeons, New York, NY
Background/Purpose: Platelet-bound complement activation products (PC4d), defined as PC4d20 net mean fluorescent intensity [MFI], or a thrombotic risk score that includes PC4d, C3 and anti-phosphatidylserine/prothrombin…
Abstract Number: 0527 • ACR Convergence 2020
Rituximab for Refractory Manifestations of the Antiphospholipid Syndrome: A Multicenter Israeli Experience
Nancy Agmon-Levin¹, Mark Berman², Liora Harel³, Merav Lidar⁴, Soad Hajyahia¹ and Daphna Paran⁵, ¹Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Scheider Children's Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel, Petach Tikva, Israel, ⁴Rheumatology unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Hod Hasharon, Israel, ⁵Department of Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: The clinical manifestations of the antiphospholipid syndrome (APS) are heterogeneous and related to anti-phospholipid antibodies (aPL). There is some evidence that B cells are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].